NCT02967939View on ClinicalTrials.gov

Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

January 23, 2019

Study Completion Date

July 15, 2019

Conditions
Hepatitis B， Chronic
Interventions
DRUG

DA-2802

DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.

DRUG

Viread®

Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.

Trial Locations (1)

08308

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT02967939 - Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients | Biotech Hunter | Biotech Hunter